EYA transcriptional coactivator and phosphatase 1Genealiases: BOP · BOR · BOS1 · OFC1 · OTFCS
Q-omics provides the consensus-scored EYA1 profile across patient tissues and cancer cell-line models. EYA1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EYA1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, EYA1 RNA expression shows 15,595 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where EYA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EYA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EYA1 survival associations across molecular data types. EYA1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EYA1 RNA expression–survival associations across cancer types. High EYA1 expression shows unfavorable associations in KIRC, LIHC, BLCA, THCA and UVM, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EYA1 RNA expression.
This table summarizes EYA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for EYA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EYA1 shows lower tumor expression in THCA, KICH, HNSC and BLCA and higher tumor expression in KIRC and COAD. The THCA box plot shows higher EYA1 RNA expression in normal versus tumor tissue (log2 FC = −1.060, t-test p < 0.001).
This table shows molecular features associated with EYA1 in patient tissues and cancer cell lines. In patient samples, EYA1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EYA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
